Intellia Therapeutics, Inc.
40 Erie Street
Suite 130
Cambridge, MA 02139
United States
857 285 6200
https://www.intelliatx.com
版塊: Healthcare
行業: Biotechnology
全職員工: 526
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Dr. John M. Leonard M.D. | President, CEO & Director | 1.12M | 無 | 1957 |
| Mr. Glenn G. Goddard CPA | Executive VP, CFO & Treasurer | 637.67k | 無 | 1971 |
| Dr. Laura Sepp-Lorenzino Ph.D. | Executive VP & Chief Scientific Officer | 720.9k | 無 | 1961 |
| Mr. James E. Basta Esq., J.D. | Executive VP, General Counsel & Corporate Secretary | 654.55k | 無 | 1966 |
| Dr. David Lebwohl M.D. | Executive VP & Chief Medical Officer | 707.56k | 無 | 1955 |
| Mr. Nessan Bermingham Ph.D. | Founder & Member of Scientific Advisor Board | 1.38M | 無 | 1973 |
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder | 無 | 無 | 1986 |
| Dr. Andrew May Ph.D. | Founder and Member of Scientific Advisor Board | 無 | 無 | 無 |
| Dr. Jennifer A. Doudna Ph.D. | Founder & Member of Scientific Advisor Board | 無 | 無 | 1964 |
| Dr. Derrick J. Rossi Ph.D. | Founder & Member of Scientific Advisor Board | 無 | 無 | 無 |
描述
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
公司管治
截至 2024年5月1日 止，Intellia Therapeutics, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：6；董事會：8；股東權利：8；現金賠償：6。
